Chadderton, Naomi and Cowen, Rachel L. and Sheppard, Freda C.D. and Robinson, Suzanne and Greco, Olga and Scott, Simon and Stratford, Ian J. and Patterson, Adam V. and Williams, Kaye J. (2005) Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. International Journal of Radiation Oncology Biology Physics, 62 (1). pp. 213-222. ISSN 0360-3016. (doi:10.1016/j.ijrobp.2005.01.031 ) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)
|The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)|
Purpose: Tumor hypoxia is unequivocally linked to poor radiotherapy outcome. This study aimed to identify enhancer sequences that respond maximally to a combination of radiation and hypoxia for use in genetic radiotherapy approaches. Methods and Materials: The influence of radiation (5 Gy) and hypoxia (1% O-2) on reporter-gene expression driven by hypoxia (HRE) and radiation (Egr-1) responsive elements was evaluated in tumor cells grown as monolayers or multicellular spheroids. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) and HIF-2 alpha protein expression was monitored in parallel. Results: Of the sequences tested, an HRE from the phosphoglycerate kinase-1 gene (PGK-18[5+]) was maximally induced in response to hypoxia plus radiation in all 5 cell lines tested. The additional radiation treatment afforded a significant increase in the induction of PGK-18[5+] compared with hypoxia alone in 3 cell lines. HIF-1 alpha/2 alpha were induced by radiation but combined hypoxia/radiation treatment did not yield a further increase. The dual responsive nature of HREs was maintained when spheroids were irradiated after delivery of HRE constructs in a replication-deficient adenovirus. Conclusions: Hypoxia-responsive enhancer element sequences are dually responsive to combined radiation and hypoxic treatment. Their use in genetic radiotherapy in vivo could maximize expression in the most radioresistant population at the time of radiation and also exploit microenvironmental changes after radiotherapy to yield additional switch-on.
|Divisions:||Faculties > Science Technology and Medical Studies > Medway School of Pharmacy|
|Depositing User:||Simon Scott|
|Date Deposited:||13 Sep 2008 18:55|
|Last Modified:||24 Jun 2014 15:35|
|Resource URI:||https://kar.kent.ac.uk/id/eprint/9639 (The current URI for this page, for reference purposes)|